title: Stereotactic radiotherapy using Novalis for skull base metastases developing with cranial nerve symptoms.
abstract: Skull base metastases are challenging situations because they often involve critical structures such as cranial nerves. We evaluated the role of stereotactic radiotherapy (SRT) which can give high doses to the tumors sparing normal structures. We treated 11 cases of skull base metastases from other visceral carcinomas. They had neurological symptoms due to cranial nerve involvement including optic nerve (3 patients), oculomotor (3), trigeminal (6), abducens (1), facial (4), acoustic (1), and lower cranial nerves (1). The interval between the onset of cranial nerve symptoms and Novalis SRT was 1 week to 7 months. Eleven tumors of 8-112 ml in volume were treated by Novalis SRT with 30-50 Gy in 10-14 fractions. The tumors were covered by 90-95% isodose. Imaging and clinical follow-up has been obtained in all 11 patients for 5-36 months after SRT. Seven patients among 11 died from primary carcinoma or other visceral metastases 9-36 months after Novalis SRT. All 11 metastatic tumors were locally controlled until the end of the follow-up time or patient death, though retreatment for re-growth was done in 1 patient. In 10 of 11 patients, cranial nerve deficits were improved completely or partially. In some patients, the cranial nerve symptoms were relieved even during the period of fractionated SRT. Novalis SRT is thought to be safe and effective treatment for skull base metastases with involvement of cranial nerves and it may improve cranial nerve symptoms quickly.
authors.affiliation: Nagoya Radiosurgery Center, Nagoya Kyoritsu Hospital, 1-172 Hokke, Nakagawa, Nagoya, Aichi, 454-0933, Japan. ymori@kaikou.or.jp
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Mori
authors.forename: Chisa
authors.initials: C
authors.lastname: Hashizume
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Yuta
authors.initials: Y
authors.lastname: Shibamoto
authors.forename: Katsura
authors.initials: K
authors.lastname: Kosaki
authors.forename: Aiko
authors.initials: A
authors.lastname: Nagai
mesh_terms: D000328:Adult; D000368:Aged; D003389:Cranial Nerve Diseases / Q000209:etiology* / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007091:Image Processing, Computer-Assisted / Q000379:methods; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D016634:Radiosurgery / Q000379:methods*; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D019292:Skull Base Neoplasms / Q000150:complications / Q000556:secondary / Q000601:surgery; D016896:Treatment Outcome
references.citation: Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):997-1003
references.pmid: 9169805
references.citation: J Neurosurg. 2006 Dec;105 Suppl:37-42
references.pmid: 18503328
references.citation: Surg Neurol. 2009 Sep;72(3):248-55; discussion 255-6
references.pmid: 18786712
references.citation: J Neurosurg. 2005 Jan;102 Suppl:230-3
references.pmid: 15662816
references.citation: Stereotact Funct Neurosurg. 2005;83(5-6):202-7
references.pmid: 16424685
references.citation: Head Neck. 2007 Jun;29(6):537-45
references.pmid: 17274059
references.citation: J Neurooncol. 2005 Oct;75(1):63-9
references.pmid: 16215817
references.citation: Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):709-15
references.pmid: 18692328
references.citation: Stereotact Funct Neurosurg. 2006;84(2-3):103-8
references.pmid: 16840820
references.citation: J Neurosurg. 2009 Oct;111(4):863-73
references.pmid: 19284227
references.citation: Int J Radiat Oncol Biol Phys. 1997 Dec 1;39(5):977-81
references.pmid: 9392534